XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of stock option activity

Outstanding Options and RSUs

    

    

    

    

Weighted-

    

Weighted-

Average

Shares

Number of

Average

Remaining

Aggregate

Available for

Shares

Exercise

Contractual

Intrinsic

(in thousands, except for contractual life and exercise price)

Grant

Outstanding

Price

Life

Value

(in years)

Balance at December 31, 2022

 

3,263

 

5,300

$

21.11

 

4.84

$

131,385

Additional shares authorized

 

3,500

Options granted

 

(497)

 

497

$

44.29

Options exercised

 

 

(265)

$

13.26

RSUs granted

(5,728)

RSUs forfeited/cancelled

760

Balance at September 30, 2023

 

1,298

 

5,532

$

23.57

4.61

$

142,513

Exercisable at September 30, 2023

 

4,525

$

13.81

3.74

$

141,977

Vested and expected to vest at September 30, 2023

 

5,466

$

23.05

4.56

$

142,478

Restricted stock units

Weighted-

Average

Grant Date

(in thousands, except for grant date fair value)

Shares

Fair Value

Balance at December 31, 2022

6,836

$

57.12

Granted

5,728

$

44.99

Vested

(2,364)

$

57.01

Cancelled/forfeited

(760)

$

50.01

Balance at September 30, 2023

9,440

$

50.28

Summary of stock-based compensation expenses

The following tables present the effect of employee and non-employee stock-based compensation expense on selected statements of operations line items for the three and nine months ended September 30, 2023 and 2022.

Three months ended September 30, 

2023

2022

    

Employee

    

Non-Employee

    

Total

    

Employee

    

Non-Employee

    

Total

(in thousands)

Cost of revenues

$

3,284

$

15

$

3,299

$

2,124

$

$

2,124

Research and development

 

18,278

 

650

 

18,928

 

12,972

 

497

 

13,469

Selling, general and administrative

 

35,233

 

271

 

35,504

 

24,524

 

221

 

24,745

Total

$

56,795

$

936

$

57,731

$

39,620

$

718

$

40,338

Nine months ended September 30, 

 

2023

2022

 

    

Employee

    

Non-Employee

    

Total

    

Employee

    

Non-Employee

    

Total

 

 

(in thousands)

Cost of revenues

$

8,669

$

24

$

8,693

$

5,903

$

$

5,903

Research and development

 

47,316

 

1,965

 

49,281

 

33,911

 

1,432

 

35,343

Selling, general and administrative

 

83,822

 

1,100

 

84,922

 

74,700

 

452

 

75,152

Total

$

139,807

$

3,089

$

142,896

$

114,514

$

1,884

$

116,398

Employee Stock Option [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of assumptions used in valuation of fair value

Three months ended September 30, 

Nine months ended September 30, 

    

2023

    

    

2022

    

2023

2022

Expected term (years)

 

6.03

 

6.05

5.20

6.03

5.12

10.00

Expected volatility

 

68.23

%

 

61.63

%

68.23

%

70.07

%

55.91

%

62.30

%

Expected dividend rate

 

%

 

%

%

%

Risk-free interest rate

 

4.18

%

 

3.15

%

3.41

%

4.18

%

1.62

%

3.15

%